Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amgen 386 With and Without Bevacizumab for Recurrent Glioblastoma
NCT01290263Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2010
- Primary completion
- Jul 2015
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of trebananib in glioblastoma multiforme (GBM) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: 6-Month Progression-Free Survival, Maximum Tolerated Dose at 28 days and 1 more. Started Dec 2010; status: completed.
02
Drugs
trebananib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT01290263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01290263.